Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-7316
Dr. Reddy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
McGaw Medical Center of Northwestern UniversityChief Residency, Internal Medicine, 2013 - 2014
Northwestern UniversityMSci, Clinical Investigation, 2012 - 2014- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2011 - 2013
- McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 2010 - 2011
David Geffen School of Medicine at UCLAClass of 2010
Certifications & Licensure
TX State Medical License 2014 - 2025
IL State Medical License 2010 - 2014
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib Start of enrollment: 2021 Apr 15
Publications & Presentations
PubMed
- 11 citationsA comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response.Lily Xu, Kaitlyn Saunders, Shao-Po Huang, Hildur Knutsdottir, Kenneth Martinez-Algarin
Cell Reports. Medicine. 2024-05-21 - 1 citationsDigital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneity.Katherine E Lake, Megan M Colonnetta, Clayton A Smith, Kaitlyn Saunders, Kenneth Martinez-Algarin
Frontiers in Cell and Developmental Biology. 2024-01-01 - 6 citationsDendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.Amrendra Kumar, Vijay Ramani, Vijaya Bharti, Daniel de Lima Bellan, Nabil Saleh
Journal for Immunotherapy of Cancer. 2023-05-01
Press Mentions
Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for MelanomaNovember 12th, 2017
Three Workshops Among Several Focusing on Clinical ScienceNovember 29th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
